Skip to content

The value of 18F-SMA -1007 PET/CT in accurate assessment of biochemical recurrence of prostate cancer and its influence on clinical treatment decision

The value of 18F-SMA -1007 PET/CT in accurate assessment of biochemical recurrence of prostate cancer and its influence on clinical treatment decision

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2100052238
Enrollment
Unknown
Registered
2021-10-23
Start date
2020-06-13
Completion date
Unknown
Last updated
2022-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

prostatic cancer

Interventions

imaging follow-up results.
Index test:18F-PSMA-1007&#32
PET/CT:SUV
TLG.

Sponsors

The First Affiliated Hospital of Harbin Medical University
Lead Sponsor

Eligibility

Sex/Gender
Male
Age
18 Years to 85 Years

Inclusion criteria

Inclusion criteria: 1. Aged 18 to 80 years; 2. The research objects are patients with clinically suspected or confirmed tumors; 3. Participants who have completed 18F-FDG and 18F-FAPI PET/CT scans successively; 4. There is at least one measurable target lesion according to the RECIST1.1 standard; 5. Participants who can provide informed consent (signed by the participant, parent or legal representative), and agree in accordance with the guidelines of the clinical research ethics committee.

Exclusion criteria

Exclusion criteria: 1. Severe abnormal liver and kidney function; 2. Those who cannot lie down for half an hour; 3. Suffer from claustrophobia or other mental illness; 4. Other situations considered by the investigator to be unsuitable for participating in the trial.

Design outcomes

Primary

MeasureTime frame
Standard uptake value;Standard uptake value max;Standard uptake value mean;Standard uptake value Minimum;Metabolic tumor volume;total lesion glycolysis;

Countries

China

Contacts

Public ContactLyu Zhehao

Department of Nuclear Medicine, the First Affiliated Hospital of Harbin Medical University

lyuzhehao@hrbmu.edu.cn+86 13206741280

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026